2023 American Academy of Neurology Abstract Website

Disclosures for "MANOEUVRE Study Design: A Study of GYM329 (RO7204239) in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)")

Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ML Bio. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma. Dr. Statland has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Statland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity . Dr. Statland has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum Therapeutics. The institution of Dr. Statland has received research support from NIH. The institution of Dr. Statland has received research support from FSHD Society. The institution of Dr. Statland has received research support from Friends of FSH Research. The institution of Dr. Statland has received research support from FSHD Canada. The institution of Dr. Statland has received research support from MDA.
Ms. Eichinger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acceleron. Ms. Eichinger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Fulcrum. Ms. Eichinger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avidity. Ms. Eichinger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DyneTherapeutic. Ms. Eichinger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Ms. Eichinger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Cure SMA. Ms. Eichinger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ology. Ms. Eichinger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for FSHD Society. The institution of Ms. Eichinger has received research support from Charcot Marie Tooth Association.
The institution of Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Morrow has received research support from Muscular Dystrophy Association.
Dr. Tasca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Tasca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen Pharma. Dr. Tasca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics.
Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fulcrum Therapeutics. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus therapeutics. Prof. Vissing has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Biopharma. Prof. Vissing has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvinas ML Biopharma. The institution of Prof. Vissing has received research support from Rigshospitalet. The institution of Prof. Vissing has received research support from UCB Pharma. The institution of Prof. Vissing has received research support from Sanofi. The institution of Prof. Vissing has received research support from NOVO Foundation.
Angela Dodman has received personal compensation for serving as an employee of F. Hoffman-La Roche Ltd.
Birgit Jaber has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Birgit Jaber has received stock or an ownership interest from F. Hoffmann-La Roche Ltd. Birgit Jaber has received personal compensation in the range of $100,000-$499,999 for serving as a Senior Safety Director with F. Hoffmann-La Roche Ltd.
Heidemarie Kletzl has received personal compensation for serving as an employee of Hoffmann-La Roche.
Tammy McIver has received personal compensation for serving as an employee of Roche. Tammy McIver has received stock or an ownership interest from Roche .
Renata SCALCO has received personal compensation for serving as an employee of Roche. Renata SCALCO has received stock or an ownership interest from Roche.
Wai Yin Yeung has nothing to disclose.
Dr. Gaki has received personal compensation for serving as an employee of Roche. Dr. Gaki has received stock or an ownership interest from Roche Products Ltd.
Dr. Wagner has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Wagner has stock in F. Hoffmann-La Roche.